Floatz logo

Lerodalcibep

Cardiovascular Risk Factor

LIB Therapeutics LLCPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Cardiovascular Risk Factor cohort.

Asset / SponsorPhaseRating
Fuzuloparib
Tulane University
Phase 1/2CCC
Zeprumetostat
Tulane University
Phase 1/2CCC
METHOTREXATE
The University of Texas at Arlington
Phase 1CC
4-OXYPIPERIDOL
The University of Texas at Arlington
Phase 1CC
Allopurinol
The University of Texas at Arlington
Phase 1CC

View all 9 →

Same molecule, other indications

Lerodalcibep is also rated in:

HypercholesterolemiaDormant
B
Indicative ·
60 / 100
View asset →
cardiovascular disorderDormant
B
Indicative ·
57 / 100
View asset →
stroke disorderDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →